CFO August Moretti retires; Uneek Mehra appointed as CFO effective Sept 11, 2023

4D Molecular Therapeutics, Inc.

August J. Moretti retired as CFO effective Sept 11, 2023; will serve as Senior Business Advisor through 2023 then consultant through Dec 2024 at $18k/month.
Uneek Mehra appointed CFO, Principal Financial and Accounting Officer; base salary $510k, target bonus 45%, option grant of 229,634 shares.
Mehra previously served as CFO at Myovant Sciences (Sept 2021-July 2023) and PACT Pharma.
Sign-on bonus of $200k in two installments; severance includes 9 months base salary and COBRA reimbursement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Uneek Mehra

Chief Financial and Business Officer

FDMT · 4D Molecular Therapeutics, Inc.

Effective: 2023-09-11
Filed: September 13, 2023, 7:59 PM ET

announced that Uneek Mehra had joined the Company as Chief Financial and Business Officer, Principal Financial Officer, Principal Accounting Officer, and Assistant Secretary of the Company.

Departed

August J. Moretti

Chief Financial Officer

FDMT · 4D Molecular Therapeutics, Inc.

Effective: 2023-09-11
Successor: Uneek Mehra
Filed: September 13, 2023, 7:59 PM ET

announced that August J. Moretti will retire as Chief Financial Officer and Assistant Secretary of the Company, effective September 11, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Uneek Mehra was appointed as Chief Financial and Business Officer at 4D Molecular Therapeutics, Inc..

Action: joined
Role: Chief Financial and Business Officer

Exact text from the filing

announced that Uneek Mehra had joined the Company as Chief Financial and Business Officer, Principal Financial Officer, Principal Accounting Officer, and Assistant Secretary of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

August J. Moretti departed as Chief Financial Officer at 4D Molecular Therapeutics, Inc..

Action: retire
Role: Chief Financial Officer

Exact text from the filing

announced that August J. Moretti will retire as Chief Financial Officer and Assistant Secretary of the Company, effective September 11, 2023.

View on SEC.gov

4D Molecular Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-233693

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.